After ischemic stroke, significant changes occur in TGF- signaling in astrocytes and microglia/macrophages [35]
Progress and Future Direction of Tamoxifen Resistance in Breast Cancer Endocrine therapy is extremely important for ER-positive breast cancer patients
Disclosures: Shweta Raina: Nothing to Disclose, Curtis Cooper: Nothing to Disclose, Jordan Feld: Mirum: Consultant, AbbVie, Bluejays, Gilead, Janssen, GSK, Roche, VIR Roche: Consultant, Bluejays: Consultant, Gilead: Consultant, Janssen: Consultant, GSK: Consultant, Roche: Consultant, VIR Biotechnology: Consultant, Altimmune, AbbVie, Gilead, Jannsen, GSK, Roche, VIR Bio: Grant/Research Support, Lisa Johnson: Nothing to Disclose, Ashley Brown: Nothing to Disclose, Anthony Martinez: Gilead: Consultant, Gilead: Speaking and Teaching, Abbvie: Consultant, Abbvie: Speaking and Teaching, Arbutus: Consultant, Braeburn: Speaking and Teaching, Sirtex: Consultant, Roche: Consultant, Syneos/VBI: Consultant, Madrigal: Speaking and Teaching, Altimune: Consultant, Brian Conway: Nothing to Disclose, Stuart Gordon: Nothing to Disclose, Tarik Asselah: Nothing to Disclose, Liz Uribe: Nothing to Disclose, Moming Li: Nothing to Disclose, Alexandru Iacob: Nothing to Disclose, John Marcinak: AbbVie: Employee, Jatinder Kaur: AbbVie: Employee, Dimitri Semizarov: Nothing to Disclose, Stanislas Pol: Nothing to Disclose 509 ROLE OF OGT-TFF2 AXIS IN INTRAHEPATIC CROSSTALK AND MASH PATHOGENESIS Lei Zhang 1 Cuijuan Han 2 Man Shrestha 1 Jiamei Le 1 Max Padian 1 Reina Desrouleaux 3 Eric Wang 2 Xiaoyong Yang 4 , 1 Department of Comparative Medicine, Yale University School of Medicine, 2 The Jackson Laboratory for Genomic Medicine, 3 Department of Cellular and Molecular Physiology, Yale University School of Medicine, 4 Department of Comparative Medicine, Cellular and Molecular Physiology, Yale School of Medicine Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a global metabolic disease that comprises a broad spectrum of liver dysfunction ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis
10.1038/s41392-023-01325-736737432 8 Silaschi M, Byrne J, Wendler O
Studies are exploring new formulations, delivery methods, and combinations of peptides and NAD+ to enhance their regenerative effects
